Halozyme Therapeutics | HALO - Aktuelle Verpflichtungen

Aktienkurs
65.36
Täglich Wechseln
-1.23 -1.85%
Monatlich
3.35%
Jährlich
8.05%
Q2 Prognose
63.96




Aktuelle Verpflichtungen Veränderung Datum
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amarin USD 194.46M 12.23M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Baxter International USD 2.97B 805M 2025-12
Cara Therapeutics USD 11.04M 362K 2025-09
Cytokinetics USD 202.45M 60.31M 2025-12
DBV Technologies USD 49.48M 60K 2025-09
Eli Lilly USD 35.23B 4.91B 2025-12
Esperion Therapeutics USD 300.81M 58.22M 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Intrexon USD 23.02M 38K 2024-06
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
MannKind USD 171.03M 61.9M 2025-12
Minerva Neurosciences USD 2.29M 381K 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
United Therapeutics USD 560.6M 14.3M 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12